This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence is now designing custom proteins in seconds—a process that once took years—paving the way for cures to diseases like cancer and antibiotic-resistant infections. Australian scientists have joined this biomedical frontier by creating bacteria-killing proteins with AI. Their new platform, built by a team of biologists and computer scientists, is part of a global movement to democratize and accelerate protein design for medical breakthroughs.
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
Yoav Shamir, Nir London bioRxiv 2025.03.19.642201 doi: [link] Recent years have seen an explosion in the prominence of covalent inhibitors as research and therapeutic tools. However, a lag in application of computational methods for covalent docking slows progress in this field. AI models such as AlphaFold3 have shown accuracy in ligand pose prediction but were never assessed for virtual screening.
In Adobe’s 2025 AI and Digital Trends report, one message rings loud and clear: the convergence of marketing and IT is essential to digital success. As AI becomes increasingly embedded in customer experience strategies, marketing and IT leaders must collaborate closely to unlock its full potential. The Rise of Agentic AI One of the most transformative ideas in the report is the rise of agentic AI, autonomous systems that collaborate across platforms to deliver hyper-personalized, real-time exper
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Prime editing treats childhood brain disease in mice By Corie Lok July 21, 2025 Breadcrumb Home Prime editing treats childhood brain disease in mice Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder that begins in infancy.
Zoledronic acid was identified as a lead hit targeting ZNF726 activity, inhibiting its proliferative effects on breast cancer cells. Zoledronic acid inhibits cellular cholesterol level through the inhibition of ZNF726 activity in breast cancer cells. Nine phytochemicals were identified from docking studies that might be used as potential therapeutics for targeting ZNF726 activity.
A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection. Researchers used a virus to deliver a healthy copy of the OTOF gene into the inner ear, improving auditory function across all ten participants in the study. The therapy worked best in young children but still benefited adults, with one 7-year-old girl regaining almost full hearing.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection. Researchers used a virus to deliver a healthy copy of the OTOF gene into the inner ear, improving auditory function across all ten participants in the study. The therapy worked best in young children but still benefited adults, with one 7-year-old girl regaining almost full hearing.
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. However, R&D stakeholders are learning that GenAI underpinned by domain expertise also enables deep dives into the broader long-term potential of their investigational asset(s) as early as the preclinical phase.
Bing Zhao, Sha Xu, Shiqing Zhou, Xiangru Jiang, Ailin Jiang, Hongrui Lei, Xin Zhai Bioorganic Chemistry, 163, 2025, 108800, [link] [link] the past two decades, covalent inhibitors have undergone a remarkable resurgence in drug discovery. Currently, targeting non-catalytic cysteine residues with acrylamide and other α,β-unsaturated carbonyl compounds is a predominate strategy, especially in the protein kinase field.
Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets By Leah Eisenstadt July 24, 2025 Breadcrumb Home Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. ABSTRACT The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years.
Scientists at ETH Zurich have broken new ground by generating over 400 types of nerve cells from stem cells in the lab, far surpassing previous efforts that produced only a few dozen. By systematically experimenting with combinations of morphogens and gene regulators, the researchers replicated the vast diversity of neurons found in the human brain.
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.
Clinical trials are expensive, slow and often limited by outdated design constraints. Placebo arms, in particular, create ethical and logistical hurdles, especially in areas like rare disease and oncology. Digital twins offer a way forward. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
You can think of the Model Context Protocol (MCP) as USB for large language models (LLMs), allowing an LLM to interact with a variety of external systems in a uniform manner. It was developed by Anthropic to solve the fundamental problem of getting a text generator (LLM) to perform real-world actions on a user’s behalf. Solving the M x N Problem With a growing number of powerful LLMs (M) and a vast universe of applications and APIs (N) for them to interact with, one would need to develop M
BURLINGAME, Calif. — July 8, 2025. Collaborative Drug Discovery (CDD) , the leading provider of data management solutions for the pharmaceutical and biotechnology industries, and deepmirror , the AI drug design platform that empowers chemists to focus on more promising drug molecules, today announced a strategic partnership integrating deepmirror with CDD Vault to enhance drug discovery.
Illinois engineers fused ultrafast imaging with smart algorithms to peek at living brain chemistry, turning routine MRIs into metabolic microscopes. The system distinguishes healthy regions, grades tumors, and forecasts MS flare-ups long before structural MRI can. Precision-medicine neurology just moved closer to reality.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Novel 1,2,3-triazole derivatives incorporating a 4-iodosulfonamide moiety were synthesized. Their antioxidant properties were evaluated using DPPH, ABTS, and CUPRAC methods. The inhibitory activity of the compounds against cholinesterases (AChE and BuChE) was investigated. An investigation of their anticancer properties against Caco-2 and PC3 cancer cell lines was also conducted.
Hundreds of life-altering conditions attack the central nervous system (CNS). Disorders such as Alzheimer’s disease , primary glioblastoma and amyotrophic lateral sclerosis (ALS) all affect the CNS and are considered fatal, while more common conditions, including depression , strokes and epilepsy , require long-term treatments. According to the World Health Organization (WHO) , neurological conditions are now the number one cause of ill health and disability across the globe, 1 highlighting the
How can you work out the function of a particular gene or protein across different cell types and functions? If you perturb it—modify it and observe the consequences—you can start to unravel what its biological role might be, and determine whether the effects are unique to one cell type or whether they propagate across different cell contexts.
Oncology drug approvals in H1 2025 In the first half of 2025, the FDA’s Center for Drug Evaluation and Research (CDER) approved a total of 16 novel drugs , with half of these drugs related to the treatment of cancer. Both the novel and supplemental oncology approvals reflected recent developmental innovations, including an increased focus on targeted, immunologically driven, and personalized oncology therapies, targeting a broad range of cancers.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The 2025 CDD User Group Meeting (UGM) Canada brought together researchers, industry experts, and thought leaders to discuss the latest advancements in drug discovery, data management, and collaborative research.
Millipedes, often dismissed as creepy crawlies, may hold the secret to future painkillers and neurological drugs. Researchers at Virginia Tech discovered unique alkaloid compounds in the defensive secretions of a native millipede species. These complex molecules, which cause disorientation in ants, interact with human neuroreceptors linked to pain and cognition.
Fernando, M. C., Craven, G. B., & Shokat, K. M. Small GTPases, 2024 15(1), 1–7. [link] KRAS is the most frequently mutated oncogene in human cancer. In multiple types of cancer, a missense mutation at codon 12 substitutes a glycine for a cysteine, causing hyperactivation of the GTPase and enhanced MAPK signalling. Recent drug discovery efforts culminating from work during the past decade have resulted in two FDA-approved inhibitors, sotorasib and adagrasib, which target the KRASG12C mutant a
Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. For Dr Jhong-Jhe ‘JJ’ You, Vice President of Antibody Discovery at AP Biosciences, these challenges are not setbacks. They are starting points. With a background in neurobiology, immuno-oncology and bispecific engineering, JJ now leads the development of antibody candidates designed to go further
PALAZESTRANT CAS 2092925-89-6 OP-1250, VU35KM56Q4 449.6 g/mol, C 28 H 36 FN 3 O (1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Palazestrant (OP-1250) is an investigationa
Highly targeted antibody-drug conjugates (ADCs) combine an antibody with a cytotoxic payload, covalently attached via a chemical linker. These “ biological missiles ” represent an exciting new advance in anti-cancer therapies and are one of the fastest-growing segments in oncology drug development. Due to their complex make-up and multiple components, analysis of their chemistry and functionality is challenging, requiring advanced assays and techniques for effective study and characterization.
A gene is the essential hereditary unit that passes traits from parents to offspring; a segment of DNA containing instructions for making a specific protein or molecule that performs a particular function in your body. And yet, despite being fundamental to our flourishing, genes can be broken. Researchers have identified nearly 10,000 monogenic diseases , or conditions caused by errors in a single gene.
Using a clever combo of iron and radical chemistry, scientists have unlocked a safer, faster way to create carbenes molecular powerhouses key to modern medicine and materials. It s 100x more efficient than previous methods.
The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.
In Part 2 of our conversation with Layla Hosseini-Gerami, Chief Data Science Officer at Ignota Labs , we explore the many forms of toxicity and how AI-powered tools like omics and cell painting are transforming early prediction in pre-clinical research. The conversation revealed important distinctions between different types of toxicity and our current ability to predict them: “For certain types of toxicity like liver and cardio, I think those are quite well understood in terms of the mech
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content